Cyntegrity, Germany’s provider of intelligent risk-based quality management (RBQM) solutions to the Life Sciences industry, has announced the launch of MyRBQM Portal - a full-service business intelligence and analytics cloud specifically designed for clinical trial purposes.
MyRBQM Portal responds to the practical implementation needs of CROs, Biopharma and MedTech enterprises transiting to risk-oriented processes mandated by today’s GCP guideline ICH E6 (R2) and EU MDR.
For more information, visit www.cyntegrity.com
Phase III Trial of Keytruda Plus Lynparza for NSCLC Stopped Due to Futility
December 7th 2023KEYLYNK-008 trial finds that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit in patients with metastatic squamous non-small cell lung cancer.
Key Phase III Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.